Advertisement
Advertisement

CRNX

CRNX logo

Crinetics Pharmaceuticals, Inc.

37.09
USD
Sponsored
+0.82
+2.26%
May 21, 16:00 UTC -4
Closed
exchange

After-Market

37.09

0.00
+0.01%

CRNX Earnings Reports

Positive Surprise Ratio

CRNX beat 9 of 32 last estimates.

28%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$15.12M
/
-$1.26
Implied change from Q1 26 (Revenue/ EPS)
+40.83%
/
+2.44%
Implied change from Q2 25 (Revenue/ EPS)
+1366.20%
/
+2.44%

Crinetics Pharmaceuticals, Inc. earnings per share and revenue

On May 07, 2026, CRNX reported earnings of -1.23 USD per share (EPS) for Q1 26, beating the estimate of -1.26 USD, resulting in a 2.51% surprise. Revenue reached 10.73 million, compared to an expected 8.68 million, with a 23.64% difference. The market reacted with a -13.82% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of -1.26 USD, with revenue projected to reach 15.12 million USD, implying an increase of 2.44% EPS, and increase of 40.83% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
logo
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
logo
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
logo
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
logo
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
logo
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-
Actual
-$0.07
Surprise
-
logo
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
logo
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
For Q1 2026, Crinetics Pharmaceuticals, Inc. reported EPS of -$1.23, beating estimates by 2.51%, and revenue of $10.73M, 23.64% above expectations.
The stock price moved down -13.82%, changed from $43.49 before the earnings release to $37.48 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 12 analysts, Crinetics Pharmaceuticals, Inc. is expected to report EPS of -$1.26 and revenue of $15.12M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement